中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
9期
7-9
,共3页
小剂量%美罗华%慢性特发性血小板减少性紫癜%研究
小劑量%美囉華%慢性特髮性血小闆減少性紫癜%研究
소제량%미라화%만성특발성혈소판감소성자전%연구
Small doses%Rituximab%Chronic idiopathic thrombocytopenic purpura%Research
目的 研究小剂量美罗华治疗慢性特发性血小板减少性紫癜(idiopathic thrombocytopenic purpura,ITP)的效果.方法 2012年2月到2013年2月,安阳市人民医院共58例患者被确诊为慢性ITP.以数字法随机分成观察组(29例)和对照组(29例).对照组给予地塞米松,40 mg/d,静脉滴注,连续4d,观察组给予小剂量美罗华100 mg/次,静脉滴注,1次/周,连续治疗4周.观察两组血小板计数(PLT)、血小板抗体水平以及治疗前后的免疫细胞水平.结果 观察组总有效率为65.52％ (19/29),显著高于对照组[37.93％ (11/29)],差异有统计学意义(P＜0.05).观察组治疗后PAIgG水平为(50.15 ±49.91) ng/107,显著低于治疗前(133.04±117.69) ng/107,以及对照组治疗后(77.23±50.11) ng/107血小板.观察组治疗后PLT水平为(72.13±0.42)×109/L,显著高于治疗前[(9.32±0.57)×109/L],以及对照组治疗后[(48.56±0.63)×109/L].观察组治疗后CD19+ CD20+为107±89,显著少于治疗前的368±274,以及对照组治疗后的241±143;观察组治疗后CD4+ CD25+ FOXP3-为(6.5±4.2)％,显著少于治疗之前[(10.4±9.3)％],以及对照组治疗后[(8.8±4.3)％].差异均有统计学意义(P均＜0.05).结论 以小剂量美罗华对慢性ITP进行治疗,可明显减少血小板有关抗体,改善免疫细胞功能,提高血小板水平,疗效明显,值得临床推荐.
目的 研究小劑量美囉華治療慢性特髮性血小闆減少性紫癜(idiopathic thrombocytopenic purpura,ITP)的效果.方法 2012年2月到2013年2月,安暘市人民醫院共58例患者被確診為慢性ITP.以數字法隨機分成觀察組(29例)和對照組(29例).對照組給予地塞米鬆,40 mg/d,靜脈滴註,連續4d,觀察組給予小劑量美囉華100 mg/次,靜脈滴註,1次/週,連續治療4週.觀察兩組血小闆計數(PLT)、血小闆抗體水平以及治療前後的免疫細胞水平.結果 觀察組總有效率為65.52％ (19/29),顯著高于對照組[37.93％ (11/29)],差異有統計學意義(P＜0.05).觀察組治療後PAIgG水平為(50.15 ±49.91) ng/107,顯著低于治療前(133.04±117.69) ng/107,以及對照組治療後(77.23±50.11) ng/107血小闆.觀察組治療後PLT水平為(72.13±0.42)×109/L,顯著高于治療前[(9.32±0.57)×109/L],以及對照組治療後[(48.56±0.63)×109/L].觀察組治療後CD19+ CD20+為107±89,顯著少于治療前的368±274,以及對照組治療後的241±143;觀察組治療後CD4+ CD25+ FOXP3-為(6.5±4.2)％,顯著少于治療之前[(10.4±9.3)％],以及對照組治療後[(8.8±4.3)％].差異均有統計學意義(P均＜0.05).結論 以小劑量美囉華對慢性ITP進行治療,可明顯減少血小闆有關抗體,改善免疫細胞功能,提高血小闆水平,療效明顯,值得臨床推薦.
목적 연구소제량미라화치료만성특발성혈소판감소성자전(idiopathic thrombocytopenic purpura,ITP)적효과.방법 2012년2월도2013년2월,안양시인민의원공58례환자피학진위만성ITP.이수자법수궤분성관찰조(29례)화대조조(29례).대조조급여지새미송,40 mg/d,정맥적주,련속4d,관찰조급여소제량미라화100 mg/차,정맥적주,1차/주,련속치료4주.관찰량조혈소판계수(PLT)、혈소판항체수평이급치료전후적면역세포수평.결과 관찰조총유효솔위65.52％ (19/29),현저고우대조조[37.93％ (11/29)],차이유통계학의의(P＜0.05).관찰조치료후PAIgG수평위(50.15 ±49.91) ng/107,현저저우치료전(133.04±117.69) ng/107,이급대조조치료후(77.23±50.11) ng/107혈소판.관찰조치료후PLT수평위(72.13±0.42)×109/L,현저고우치료전[(9.32±0.57)×109/L],이급대조조치료후[(48.56±0.63)×109/L].관찰조치료후CD19+ CD20+위107±89,현저소우치료전적368±274,이급대조조치료후적241±143;관찰조치료후CD4+ CD25+ FOXP3-위(6.5±4.2)％,현저소우치료지전[(10.4±9.3)％],이급대조조치료후[(8.8±4.3)％].차이균유통계학의의(P균＜0.05).결론 이소제량미라화대만성ITP진행치료,가명현감소혈소판유관항체,개선면역세포공능,제고혈소판수평,료효명현,치득림상추천.
Objective To study the effect of small doses of rituximab on chronic idiopathic thrombocytopenic purpura(ITP).Methods From February 2012 to February 2013,in the People's Hospital of Anyang,a total of 58 patients were diagnosed as chronic ITP.They were randomly divided into the observation group(29 cases) and the control group (29 cases),the patients in the control group were treated with dexamethasone,40 mg/d,intravenous drip,lasted for 4 d,while the patients in the observation group were treated with small doses of rituximab,100 mg/times,intravenous drip,1 time/week,lasted for 4 weeks.The effects on platelet recovery,platelet antibody levels as well as the level of immune cells were observed.Results The total effective rate was 65.52％ (19/29) in the observation group,which was significantly higher than that in the control group [37.93％ (11/29)].There were significant differences (P ＜ 0.05).The PAIgG level in the observation group after treatment was (50.15 ± 49.91)ng/107,which was significantly lower than that before treatment [(133.04 ±117.69)ng/107 PAL],and that in the control group after treatment (77.23 ±50.11)ng/107 PAL].The PLT level in the observation group after treatment was (72.13 ±0.42) × 109/L,which was significantly lower than that before treatment [(9.32 ± 0.57) × 109/L],and the control group after treatment [(48.56 ±0.63) × 109/L].After treatment,CD19+ CD20+ was 107 ± 89 in the observation group,which was significantly less than that before treatment (368 ± 274),and that in the control group after treatment (241 ± 143); CD4+ CD25 + FOXP3-was 6.5 ± 4.2 in the observation group after treatment,which was significantly lower than that before treatment (10.4 ± 9.3),and that in the control group after treatment (8.8 ± 4.3).There were significant differences (Pall ＜ 0.05).Conclusions Small dose of rituximab in the treatment of chronic ITP,can significantly reduce platelet related antibodies,improve patients' immune cell function and elevate the level of platelet,which has good efficacy and is worthy of clinical recommendation.
